Metotrexato Accord

Methotrexate, the active ingredient in Metotrexato Accord, is an antimetabolite presented as a sterile injectable for intraarterial, intramuscular and intrathecal use. It is employed to treat autoimmune disorders and certain cancers in adults and children. GNH USA supplies Metotrexato Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Methotrexate acts on rapidly dividing cells and immune pathways, making it useful across several disease families. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin cell proliferation and plaque formation. - Acute lymphoblastic leukemia: induces remission by inhibiting malignant lymphoblast growth. - Non‑Hodgkin lymphoma: impedes tumor cell replication in certain lymphoma subtypes. - Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting: gastrointestinal upset occurring shortly after administration. - Fatigue: persistent tiredness not relieved by rest. - Mouth sores: ulceration of oral mucosa. - Elevated liver enzymes: mild hepatic irritation detectable on labs. - Low blood counts: mild leukopenia or anemia.

Serious or Rare Side Effects: - Severe liver toxicity: potential for hepatitis or fibrosis with prolonged use. - Pulmonary fibrosis: progressive lung scarring causing breathlessness. - Severe bone marrow suppression: pancytopenia requiring medical intervention. - Renal impairment: reduced kidney function affecting drug clearance.

Methotrexate requires careful monitoring and patient education. - Pregnancy contraindication: drug is teratogenic and must not be used in pregnancy (Category X). - Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic monitoring: perform baseline and regular liver function tests. - Blood counts: conduct complete blood count monitoring to detect cytopenias. - Drug interactions: avoid concomitant use with high‑dose NSAIDs or other folate antagonists. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (high‑dose NSAIDs): increase risk of renal toxicity. - Proton pump inhibitors: may raise methotrexate plasma levels. - Trimethoprim‑sulfamethoxazole: potentiates myelosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine or mycophenolate: additive immunosuppression. - Live vaccines: risk of infection due to immunosuppression. - Alcohol: may exacerbate hepatic toxicity.